Navigation Links
Surveyed U.S. Neurologists Would Prescribe Biogen Idec's Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
Date:4/8/2013

BURLINGTON, Mass., April 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicated that they would prescribe Biogen Idec's Tecfidera to 20 percent of their patients with relapsing-remitting multiple sclerosis (RR-MS). Decision Resources forecasts that Tecfidera will earn a patient share similar to surveyed neurologists' estimate in the U.S. RR-MS market by 2021, owing to its robust efficacy—specifically, a greater reduction in annualized relapse rate (ARR) relative to first-line agents—and a strong safety profile relative to the most effective current therapies, such as Biogen Idec's Tysabri.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Where Do Physicians and Payers Signal the Greatest Need—and Greatest Opportunity—for New Therapeutic Advances? also finds that, according to insights from surveyed U.S. and European neurologists and managed care organizations' (MCO) pharmacy directors, an increased effect in preventing sustained disability progression is one of the greatest unmet needs in RR-MS. Clinical data and the opinions of interviewed thought leaders indicate that Genzyme/Sanofi/Bayer HealthCare's emerging agent Lemtrada has demonstrated the potential to partially fulfill this unmet need.

Surveyed U.S. MCO pharmacy directors are also particularly receptive to new RR-MS therapies that offer a greater reduction in ARR over currently available therapies.

"We expect that several emerging agents, notably Lemtrada and potentially Roche/Genentech's ocrelizumab, will match the improvements on reduction in ARR that surveyed U.S. payers indicated would be required to achieve widespread inclusion and price premiums on MCO formularies," said Decision Resources Analyst John Crowley , Ph.D.

The report also finds that surveyed U.S. and European neurologists agree that reduction in ARR and the risk of serious or life-threatening sides effects are attributes that most influence their prescribing decisions in RR-MS—findings that likely underlie their positive outlook for Tecfidera.

Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec's daclizumab—have advantages in reducing ARR over Teva's Copaxone, the sales-leading agent for treatment of RR-MS. The unique risk/benefit profiles of new therapeutic alternatives will be heavily scrutinized as neurologists incorporate them into the evolving MS treatment algorithm.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
2. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
3. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
4. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
5. Protected Classes Prescription Drug Mandates Would Hike Small Business Costs, Drug Company Profits
6. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
7. Free Webinar Helps Physicians and Pharmacists Learn How to ePrescribe Controlled Substances
8. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
9. BioGenex and Abbott Molecular Conclude Successful Partnership
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... FRANCISCO , February 20, 2017 ... expected to reach USD 58.4 billion by 2025, ... Research, Inc. The market is driven by technological ... serve future growth opportunities to the market. For ... with an aim of identifying emerging viruses and ...
(Date:2/20/2017)... LONDON , February 20, 2017 Acute, Chronic ... is expected to grow at a CAGR of 7% from 2016-2021 and ... a CAGR of 6% from 2016 to 2027. The market is estimated ... ... Read on to discover how you can exploit the future business ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 20, 2017 , ... Houston dentist , Dr. Nazari, ... at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for emergencies ... risk for serious complications and often experience severe pain. Not only does prompt ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital ... a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood ... the Pepin Family Foundation. , “We greatly appreciate this gift from Constellation Brands. ...
(Date:2/19/2017)... RI (PRWEB) , ... February 19, 2017 , ... ... is proven to result in better care, and MEDfx and the Delaware Health ... state of Delaware. , As the nation’s first state-wide health information exchange, DHIN ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
Breaking Medicine News(10 mins):